Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Physiol
2004 Oct 01;560Pt 1:37-49. doi: 10.1113/jphysiol.2004.065003.
Show Gene links
Show Anatomy links
State-dependent trapping of flecainide in the cardiac sodium channel.
Ramos E
,
O'leary ME
.
???displayArticle.abstract???
Flecainide is a Class I antiarrhythmic drug and a potent inhibitor of the cardiac (Nav1.5) sodium channel. Although the flecainide inhibition of Nav1.5 is typically enhanced by depolarization, the contributions of the open and inactivated states to flecainide binding and inhibition remain controversial. We further investigated the state-dependent binding of flecainide by examining its inhibition of rapidly inactivating and non-inactivating mutants of Nav1.5 expressed in Xenopus oocytes. Applying flecainide while briefly depolarizing from a relatively negative holding potential resulted in a low-affinity inhibition of the channel (IC(50) = 345 microM). Increasing the frequency of stimulation potentiated the flecainide inhibition (IC(50) = 7.4 microM), which progressively increased over the range of voltages where Nav1.5 channels activated. This contrasts with sustained depolarizations that effectively stabilize the channels in inactivated states, which failed to promote significant flecainide inhibition. The voltage sensitivity and strong dependence of the flecainide inhibition on repetitive depolarization suggests that flecainide binding is facilitated by channel opening and that the drug does not directly bind to closed or inactivated channels. The binding of flecainide to open channels was further investigated in a non-inactivating mutant of Nav1.5. Flecainide produced a time-dependent decay in the current of the non-inactivating mutant that displayed kinetics consistent with a simple pore blocking mechanism (K(D) = 11 microM). At hyperpolarized voltages, flecainide slowed the recovery of both the rapidly inactivating (tau = 81 +/- 3 s) and non-inactivating (tau = 42 +/- 3 s) channels. Mutation of a conserved isoleucine of the D4S6 segment (I1756C) creates an alternative pathway that permits the rapid diffusion of anaesthetics out of the Nav1.5 channel. The I1756C mutation accelerated the recovery of both the rapidly inactivating (tau = 12.6 +/- 0.4 s) and non-inactivating (tau = 7.4 +/- 0.1 s) channels, suggesting that flecainide is trapped and not tightly bound within the pore when the channels are closed or inactivated. The data indicate that flecainide rapidly gains access to its binding site when the channel is open and inhibits Na(+) current by a pore blocking mechanism. Closing of either the activation or the inactivation gate traps flecainide within the pore resulting in the slow recovery of the drug-modified channels at hyperpolarized voltages.
Anderson,
Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.
1989, Pubmed
Anderson,
Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.
1989,
Pubmed
Anno,
Interactions of flecainide with guinea pig cardiac sodium channels. Importance of activation unblocking to the voltage dependence of recovery.
1990,
Pubmed
Bean,
Lidocaine block of cardiac sodium channels.
1983,
Pubmed
Benhorin,
Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
2000,
Pubmed
Brugada,
Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts.
2000,
Pubmed
Cardiac Arrhythmia Suppression Trial (CAST) Investigators,
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
1989,
Pubmed
Clarkson,
Evidence for two components of sodium channel block by lidocaine in isolated cardiac myocytes.
1988,
Pubmed
Courtney,
Mechanism of frequency-dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA.
1975,
Pubmed
Desaphy,
Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block.
2004,
Pubmed
Grant,
Block of wild-type and inactivation-deficient cardiac sodium channels IFM/QQQ stably expressed in mammalian cells.
2000,
Pubmed
Henthorn,
Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group.
1991,
Pubmed
Hille,
Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction.
1977,
Pubmed
Hondeghem,
Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs.
1984,
Pubmed
Hondeghem,
Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels.
1977,
Pubmed
Kuo,
Na+ channels must deactivate to recover from inactivation.
1994,
Pubmed
Lee,
Cardiac-specific external paths for lidocaine, defined by isoform-specific residues, accelerate recovery from use-dependent block.
2001,
Pubmed
,
Xenbase
Liu,
Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations.
2002,
Pubmed
Liu,
Common molecular determinants of flecainide and lidocaine block of heart Na+ channels: evidence from experiments with neutral and quaternary flecainide analogues.
2003,
Pubmed
Nagatomo,
Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide.
2000,
Pubmed
Nitta,
States and sites of actions of flecainide on guinea-pig cardiac sodium channels.
1992,
Pubmed
O'Leary,
Cocaine binds to a common site on open and inactivated human heart (Na(v)1.5) sodium channels.
2002,
Pubmed
,
Xenbase
O'Leary,
Closing and inactivation potentiate the cocaethylene inhibition of cardiac sodium channels by distinct mechanisms.
2003,
Pubmed
,
Xenbase
O'Leary,
A molecular link between activation and inactivation of sodium channels.
1995,
Pubmed
Qu,
Molecular determinants of drug access to the receptor site for antiarrhythmic drugs in the cardiac Na+ channel.
1995,
Pubmed
,
Xenbase
Ragsdale,
Molecular determinants of state-dependent block of Na+ channels by local anesthetics.
1994,
Pubmed
,
Xenbase
Ragsdale,
Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels.
1996,
Pubmed
Sanchez-Chapula,
Voltage- and use-dependent effects of lidocaine on sodium current in rat single ventricular cells.
1983,
Pubmed
Sheets,
Molecular action of lidocaine on the voltage sensors of sodium channels.
2003,
Pubmed
Starmer,
Mechanisms of use-dependent block of sodium channels in excitable membranes by local anesthetics.
1984,
Pubmed
Sunami,
Structural and gating changes of the sodium channel induced by mutation of a residue in the upper third of IVS6, creating an external access path for local anesthetics.
2001,
Pubmed
,
Xenbase
Viswanathan,
Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes.
2001,
Pubmed
Wang,
State-dependent block of wild-type and inactivation-deficient Na+ channels by flecainide.
2003,
Pubmed
West,
A cluster of hydrophobic amino acid residues required for fast Na(+)-channel inactivation.
1992,
Pubmed
,
Xenbase
Windle,
Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
2001,
Pubmed